Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review

Journal of Spinal Cord Medicine

Volumn 36, Issue 5, 2013, Pages 402-419

  Linsenmeyer, Todd A ^a,b,c  

^a KESSLER INSTITUTE FOR REHABILITATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c KESSLER FOUNDATION   (United States)

Author keywords

Anticholinergic drugs; Botulinum neurotoxin; Detrusor overactivity; Detrusor sphincter dyssynergia; Multiple sclerosis; Neurogenic bladder; Spinal cord injuries

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NERVE GROWTH FACTOR; PLACEBO; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

AUTONOMIC DYSREFLEXIA; BLADDER CONTRACTION; BLADDER PRESSURE; BOTULISM; CERVICAL DYSTONIA; DETRUSOR DYSSYNERGIA; DRUG FATALITY; DRUG USE; DYSPHAGIA; EXOCYTOSIS; HEMATURIA; HUMAN; HYPERHIDROSIS; INJECTION SITE PAIN; INTERMITTENT CATHETERIZATION; MEDICATION COMPLIANCE; MICTURITION; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROGENIC DETRUSOR OVERACTIVITY; NEUROMUSCULAR SYNAPSE; OVERACTIVE BLADDER; PARAPLEGIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SYRINGOMYELIA; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION;

BOTULINUM TOXINS, TYPE A; HUMANS; NEUROMUSCULAR AGENTS; SPINAL CORD INJURIES; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 84883429478     PISSN: 10790268     EISSN: 20457723     Source Type: Journal    
DOI: 10.1179/2045772313Y.0000000116     Document Type: Review

References (75)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78. (Pubitemid 34195211)
2. Abrams P, Andersson KE, Birder L, Brubaker L, Cardoz L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29(1):213-40.
3. Linsenmeyer TA. Neurogenic bladder following spinal cord injury. In: Kirshblum S, Campagnolo DI (eds.) Spinal cord medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. p. 211-41.
4. Anderson KD, Borisoff JF, Johnson RD, Stiens SA, Elliott SL. The impact of spinal cord injury on sexual function: concerns of the general population. Spinal Cord 2007;45(5):328-37. (Pubitemid 46701469)
5. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388-95. (Pubitemid 351623990)
6. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29(5):527-73.
7. Tempkin A, Sullivan G, Paldi J, Perkash I. Radioisotope renography in spinal cord injury. J Urol 1985;133(2):228-30. (Pubitemid 15158414)
8. Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults (Review). Cochrane Database Syst Rev 2009;18(4):CD003781.
9. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6(3):243-62.
10. Linsenmeyer TA, Campagnolo DI, Chou IH. Silent autonomic dysreflexia during voiding in men with spinal cord injuries. J Urol 1996;155(2):519-22. (Pubitemid 26023536)
11. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25(5):441-5.
12. Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL, Jr, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011;30(3):395-401.
13. Van Ermengem E. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskr 1897;26:1-56.
14. PDR (package insert) (Allergan Botox®) [accessed 2012 May 24]. Available from: https://hcp.botoxmedical.com/
15. Verheyden J, Blitzer A. Other noncosmetic uses of Botox®. Dis Mon 2002;48(3):357-66. (Pubitemid 35007060)
16. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139(5):919-22.
17. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692-7. (Pubitemid 30637604)
18. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity; a randomized, double blind, placebo-controlled trial. Eur Urol 2011;60(4):742-50.
19. [Verified 2012 Feb 9]. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm269509.htm
20. [accessed 2012 Feb 5]. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm175013.htm
21. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011;305(1):89-90.
22. World Health Organization. Guidelines on the use of international nonproprietary names (INNS) for pharmaceutical substances. Geneva, Switzerland: World Health Organization; 1997 [accessed 2012 May 9]. Available from: http://whqlibdoc.who.int/hq/1997/WHO-PHARM-S-NOM-1570.pdf
23. Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Tekeshi K, Moriishi K, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996;64(5):1589-94. (Pubitemid 26129820)
24. Hirai Y. Clostridium botulinum and botulinum neurotoxin [Japanese]. Brain Nerve 2011;63(7):755-61.
25. Meier T, Wallace BG. Formation of the neuromuscular junction: molecules and mechanisms. BioEssays 1998;20(10):819-29. (Pubitemid 28486018)
26. Burnstock G. Neurotransmitters and tropic factors in the autonomic nervous system. J Physiol 1981;313:1-35. (Pubitemid 11125559)
27. Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008;5(6):319-28. (Pubitemid 351818884)
28. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005;5(3):274-9. (Pubitemid 40674251)
29. Coelho A, Dinis P, Pinto R, Gorgal T, Silva C, Silva A, et al. Distribution of the high-affinity binding site and intra cellular target of botulinum toxin type A in the human bladder. Eur Urol 2010;57(5):884-90.
30. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96(6):3200-5. (Pubitemid 29148868)
31. Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004;46(6):784-91. (Pubitemid 39488414)
32. Schulte-Baukloh H, Zurawski TH, Knispel HH, Miller K, Haferkamp A, Dolly JO. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007;100(5):1075-80. (Pubitemid 47537663)
33. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord injured rats. Urology 2005;66(1):208-12. (Pubitemid 41002229)
34. Yokoyama T, Chancellor M, Oguma K, Yamamoto Y, Suzuki T, Kumon H, et al. Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 2012;19(3):202-15.
35. Conte A, Giannantoni A, Proietti S, Giovannozzi S, Fabbrini G, Rossi A, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol 2012;19(5):725-32.
36. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174(3):977-83.
37. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45(4):510-15. (Pubitemid 38376219)
38. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174(1):196-200. (Pubitemid 40825713)
39. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47(5):653-9. (Pubitemid 40521915)
40. Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injury. Neurourol Urodyn 2011;30(8):1541-5.
41. Karsenty G, Denys P, Amarenco G, De Seze M, Game? X, Haab F, et al. Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review of the literature. Eur Urol 2008;53(2):275-87. (Pubitemid 350296587)
42. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62(5):452-57. (Pubitemid 350308769)
43. Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G, et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008;53(5):1013-19.
44. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusotial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55(3):705-11.
45. Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol 2011;37(5):642-8.
46. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised placebo-controlled, double-blinded study. Scand J Urol Nephrol 2007;41(4):335-40. (Pubitemid 47357195)
47. DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improving therapies. Curr Opin Neurol 2002;15(3):271-9.
48. Kuo HC. Therapeutic effects of suburothelial injection of botulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006;67(2):232-6.
49. Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol 2006;8(4):198-208.
50. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol 2011;60(4):784-95.
51. Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol 2007;33(2):132-41.
52. Product information [accessed 2012 Feb 9]. Available from: http://www.allergan.com/assets/pdf/botox-pi.pdf
53. L'Hommedieu C, Stough R, Brown L, Kettrick R, Polin R. Potentiation of neuromuscular weakness in infant botulism by aminoglycosides. J Pediatr 1979;95(6):1065-70. (Pubitemid 10249812)
54. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007;52(6):1729-35. (Pubitemid 350064538)
55. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68(6):1193-7. (Pubitemid 44880353)
56. Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008;53(6):1245-53. Epub 2008 Mar 7.
57. Compeérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier- Kastler E. Histological features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50(5):1058-64. (Pubitemid 44486475)
58. Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of urinary tract infections. Eur Urol 2008;53(3):613-18.
59. Boy S, Seif C, Braun PM, Bremer J, Bugdorfer H, Chalaen R, et al. Retrospective analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving Botox® therapy. Eur Urol Suppl 2008;7(3):212.
60. Azadzoi KM, Pontari M, Vlachiotis J, Siroky MB. Canine bladder blood flow and oxygenation: changes induced by filling, contraction and outlet obstruction. J Urol 1996;155(4):1459-65. (Pubitemid 26081272)
61. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum Toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52(3):850-8.
62. Hori S, Patki P, Attar KH, Ismail S, Vasconcelos JC, Shah PJ. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int 2009;104(2):216-20.
63. Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin Aversus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181(5):613-8.
64. Wefer B, Ehlken B, Bremer J, Burgdörfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (Botox®) therapy in Germany. World J Urol 2010;28(3):385-90.
65. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49(3):519-27. (Pubitemid 43259563)
66. National Institute on Disability and Rehabilitation Research. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. January 27-29, 1992. J Am Paraplegia Soc 1992;15(3):194-204.
67. Dressler D, Hallett M. Immunological aspects of Botox®, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006;13(Suppl 1):11-15.
68. Consortium for Spinal Cord Medicine. Acute management of autonomic dysreflexia: adults with spinal cord injury presenting to health-care facilities. J Spinal Cord Med 2002;25(Suppl 1):S67-88.
69. Narayanan UG. Botulinum toxin: does the black box warning justify change in practice? (Commentary). Dev Med Child Neurol 2011;53(2):101-2.
70. O'Flaherty SJ, Janakan V, Morrow AM, Scheinberg AM, Waugh MC. Adverse events and health status following botulinum toxin A injections in children with cerebral palsy. Dev Med Child Neurol 2011;53(2):125-30.
71. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40(11):599-600. (Pubitemid 35305668)
72. Smaldone MC, Ristau BT, Leng WW. Botulinum toxin therapy for neurogenic detrusor overactivity. Urol Clin N Am 2010;37(4):567-80.
73. da Silva CM, Cruz F. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? Curr Opin Urol 2009;19(4):347-52.
74. Chancellor MB. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2010;42(2):383-91.
75. Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, et al. Phase 3. Efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic overactivity. J Urol 2012;187:213-39.